JP7434299B2 - インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 - Google Patents

インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 Download PDF

Info

Publication number
JP7434299B2
JP7434299B2 JP2021518432A JP2021518432A JP7434299B2 JP 7434299 B2 JP7434299 B2 JP 7434299B2 JP 2021518432 A JP2021518432 A JP 2021518432A JP 2021518432 A JP2021518432 A JP 2021518432A JP 7434299 B2 JP7434299 B2 JP 7434299B2
Authority
JP
Japan
Prior art keywords
insulin
egf
fusion protein
gaqp
gglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504153A5 (cg-RX-API-DMAC10.html
JP2022504153A (ja
Inventor
マルティン・ヴェルナー・ボルクセニウス・ミュンツェル
スサンネ・ホストロプ
グロ・クリットガード・ポールセン
マティアス・ノーマン
トマス・ボーグラム・ケルスン
クラウディア・ウルリク・ヒョリンハード
ペーター・マセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2022504153A publication Critical patent/JP2022504153A/ja
Publication of JP2022504153A5 publication Critical patent/JP2022504153A5/ja
Application granted granted Critical
Publication of JP7434299B2 publication Critical patent/JP7434299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021518432A 2018-10-05 2019-10-04 インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 Active JP7434299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18198892 2018-10-05
EP18198892.4 2018-10-05
PCT/EP2019/076889 WO2020070276A1 (en) 2018-10-05 2019-10-04 Bifunctional compounds comprising insulin peptides and egf(a) peptides

Publications (3)

Publication Number Publication Date
JP2022504153A JP2022504153A (ja) 2022-01-13
JP2022504153A5 JP2022504153A5 (cg-RX-API-DMAC10.html) 2022-10-12
JP7434299B2 true JP7434299B2 (ja) 2024-02-20

Family

ID=64017248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518432A Active JP7434299B2 (ja) 2018-10-05 2019-10-04 インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物

Country Status (8)

Country Link
US (1) US11649269B2 (cg-RX-API-DMAC10.html)
EP (1) EP3861017A1 (cg-RX-API-DMAC10.html)
JP (1) JP7434299B2 (cg-RX-API-DMAC10.html)
CN (1) CN112789289A (cg-RX-API-DMAC10.html)
AR (1) AR116605A1 (cg-RX-API-DMAC10.html)
MA (1) MA53809A (cg-RX-API-DMAC10.html)
TW (1) TW202028229A (cg-RX-API-DMAC10.html)
WO (1) WO2020070276A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HUE062719T2 (hu) 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2011117401A1 (en) 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2296694B1 (en) 2008-04-23 2015-08-05 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
CN104558199B (zh) 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
BR112018002416A2 (pt) 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2011117401A1 (en) 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents

Also Published As

Publication number Publication date
MA53809A (fr) 2022-01-12
US11649269B2 (en) 2023-05-16
WO2020070276A1 (en) 2020-04-09
EP3861017A1 (en) 2021-08-11
US20220009989A1 (en) 2022-01-13
AR116605A1 (es) 2021-05-26
TW202028229A (zh) 2020-08-01
JP2022504153A (ja) 2022-01-13
CN112789289A (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
JP2022504153A (ja) インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物
US11117947B2 (en) Double-acylated GLP-1 derivatives
US11008375B2 (en) GIP-GLP-1 dual agonist compounds and methods
JP6121992B2 (ja) ポリペプチド
JP6069198B2 (ja) Ｎ末端が修飾されたｆｇｆ２１化合物
US9012398B2 (en) Acylated exendin-4 compounds
JP6179864B2 (ja) グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
US20240025957A1 (en) Insulin Derivative
JP6227629B2 (ja) ヒトアミリン類似体
CN103596583B (zh) 新型胰高血糖素类似物
JP2021035989A (ja) 脂肪酸置換基を有するｅｇｆ（ａ）類似体
KR20110040760A (ko) 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
JP2016183177A (ja) 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
CN102933598A (zh) 新型胰高血糖素类似物
US20140303083A1 (en) GLP-1 Derivatives
KR20170075779A (ko) Gip 효능제 화합물 및 방법
KR20210005674A (ko) 글루카곤-유사 펩티드 1(glp-1) 융합 펩티드 커플링된 사이클릭 펩티드 티로신 티로신 접합체 및 이의 용도
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
CN104968674A (zh) 具有胆固醇流出活性的新颖的glp-1受体激动剂
JP2015513544A (ja) Ｇｌｐ−１プロドラッグ
KR20200037793A (ko) 이기능성 화합물
CA2988841C (en) Protease-resistant lipidated glp-1 analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7434299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150